LifeMap Sciences, a Subsidiary of BioTime (BTX), Reports Its Databases Currently Utilized by an Estimated Two Million Unique Visitors Annually According to Google Inc.Analytics
2/11/2013 10:02:46 AM
ALAMEDA, Calif.--(BUSINESS WIRE)--LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT:BTX), announced today that according to Google Analytics, the Company’s databases have attracted over two million unique visitors in the previous 12 months. Since the announcement of the acquisition of Xennex in May 2012, LifeMap launched LifeMap Discovery™, a database resource for stem cell research, and MalaCards, a database with nearly 17,000 human disease entries. These assets, combined with GeneCards®, a compendium of human genes, provide an integrated database suite with diverse commercial opportunities in science and medicine. LifeMap Sciences holds the exclusive worldwide license to market GeneCards® and MalaCards from Yeda Research and Development Company Ltd., the commercial arm of the Weizmann Institute of Science. LifeMap Discovery™ is a database owned and developed by LifeMap Sciences. In this update, LifeMap describes the nature of its current users, and outlines for the first time its goals for 2013 in marketing products to this user base.